Black Diamond lays off 30% of its workforce and culls a drug from its 'MasterKey' chest

Kyle LaHucik

Senior Reporter

With every round of layoffs, the doldrums of the biotech bear market get ever darker and more depressing. Black Diamond Therapeutics is the latest to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Black Diamond lays off 30% of its workforce and culls a drug from its 'MasterKey' chest

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Black Di­a­mond lays off 30% of its work­force and culls a drug from its 'Mas­terKey' chest

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Black Diamond lays off 30% of its workforce and culls a drug from its 'MasterKey' chest